Trials / Active Not Recruiting
Active Not RecruitingNCT03639948
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- University of Kansas Medical Center · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemotherapy and surgery, with or without radiation therapy. However, because TNBC is usually more aggressive, harder to treat, and more likely to come back, it is associated with poor long-term outcomes (survival rates) when compared to other types of breast cancer. Therefore, researchers are studying how new drugs and treatment combinations can improve the outcome of patients with TNBC. This study will test effectiveness of immune therapy (Pembrolizumab is an "immunotherapy" that is expected to work with the body's immune system to help fight cancer) in combination with chemotherapy given before surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | Intravenous solution |
| DRUG | Docetaxel | Intravenous solution |
| DRUG | Pembrolizumab | Intravenous solution |
| DRUG | Pegfilgrastim | Injectable product |
Timeline
- Start date
- 2018-09-04
- Primary completion
- 2022-01-27
- Completion
- 2024-11-01
- First posted
- 2018-08-21
- Last updated
- 2024-04-11
- Results posted
- 2024-04-11
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03639948. Inclusion in this directory is not an endorsement.